

CareDx at ISHLT 2025 | Leading the Way in Innovative Transplant Research with >60 Accepted Abstracts



Marilyn W, heart transplant recipient



Dual Testing is Changing the Practice of Post-Transplant Surveillance: Learn from Top Abstracts



AVOID UNNECESSARY BIOPSIES

Redundant Biopsies Are Not Associated with Improved Outcomes After Heart Transplant

April 30th, 8:12–8:20 AM | J. Teuteberg | Room 311

One third of HeartCare tests were associated with redundant biopsies.

✓ Trust HeartCare's dual testing to avoid redundant biopsies.



IMPROVE PROGNOSTICATION

Abnormal Dual Molecular Testing Confers Risk Even with a Negative Biopsy After Heart Transplantation (HT)

April 30th, 8:36–8:44 AM | N. Uriel | Room 311

A positive HeartCare is associated with adverse outcomes even with a negative biopsy.

✓ HeartCare's dual testing provides prognostic information independent of biopsies.



RISK STRATIFY YOUR PATIENTS

Absolute Value of GEP and dd-cfDNA Identifies Risk of ACR in Patients with Discordant Results

April 29th, 4:30–5:30 PM | Poster Hall | P03 CARD-H - POSTER SESSION 3 – Poster #1345

A definitively negative AlloSure or AlloMap as part of discordant dual testing reduces the risk of ACR

✓ HeartCare's dual testing allows for precise risk stratification



AlloSure is a Reliable Non-Invasive Marker of Allograft Injury



ADD CLINICAL VALUE

Utilization of Donor-Derived Cell-Free DNA (dd-cfDNA) in Lung Transplant Recipients

Apr 29th, 4:30– 5:30 PM | Poster Hall | Session P03 PULM-L - POSTER SESSION 3 : Poster #1627

Longitudinal testing demonstrated AlloSure levels rose at the time of ACR rejection and declined in response to rejection treatment

✓ AlloSure Lung trends correlated with the onset and treatment of ACR

Session Type	Abstract Title	Abstract First Author	Session Date	Time	Location
HEART					
How is molecular testing changing practice?					
Oral Session 30	0238 - Redundant Biopsies Are Not Associated with Improved Outcomes After Heart Transplant (SHORE Study)	J. Teuteberg	30-Apr	8:12–8:20am	Room 311
Oral Session 31	0187 - Abnormal Gene Expression Profiling (GEP) and Donor-Derived Cell-Free DNA (dd-cfDNA) is Associated with Less Prednisone Weaning (SHORE Study)	A. Alam	29-Apr	3:48–3:56pm	Ballroom B
Poster 3 Cardiology	1377 - Utility of Gene Expression Profiling & cfDNA in Prednisone Weaning & mTOR Inhibitor Conversion in Heart Transplant Recipients	F. Ishaq	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1351 - Less is More: 5-Year Outcomes After Adoption of Early Dual Non-Invasive Monitoring After Heart Transplant	E. Henricksen	29-Apr	4:30–5:30pm	Poster Hall
What are some novel ways to use molecular testing for diagnosis and prognosis?					
Oral Session 30	0240 - Abnormal Dual Molecular Testing Confers Risk Even with a Negative Biopsy After Heart Transplantation (HT) (SHORE Study)	N. Uriel	30-Apr	8:36-8:44am	Room 311
Poster 3 Cardiology	1336 - Association Between Early Gene Expression Profiling Scores and Renal Dysfunction Following Heart Transplantation (SHORE Study)	A. Kao	29-Apr	4:30–5:30pm	Poster Hall
Oral Session 28	0165 - Quilty Lesions Are Associated with Increased Rates of Molecular Rejection	S. Rahman	29-Apr	10:00–10:08am	Room 312
Oral Session 28	0169 - Utilization of Novel Cell-Free DNA and PU.1+CD31 Double Stain Assays Improves Diagnostic Accuracy of Antibody-Mediated Rejection in Cardiac Transplant Recipients	K.C.Dewan	29-Apr	10:48–10:56am	Room 312
Oral Session 28	0165 - Beyond the Surface: Unveiling Molecular Antibody-Mediated Rejection in Low-Grade Histological Cellular Rejection	S. Rahman	29-Apr	10:12–10:20am	Room 312
Oral Session 31	0185 - Very High Donor-Derived Cell-Free DNA Levels Are Associated with Increased Mortality Rates in Heart Transplant Recipients	C.M. Moeller	29-Apr	3:24–3:32pm	Ballroom B
Mini Oral 14	0415 - Donor Derived Cell Free DNA Distinguishes Between Discrepant Biopsy and MMDx Results	H.J. Tadros	29-Apr	4:36-4:40pm	Room 312
Poster 1 Cardio	0537 - A Hidden Aggressor: Endothelial Cell Antibody Mediated Rejection in a Heart Transplant Recipient	P. Prasad	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pediatrics	0711 - Liquid Biopsy as a Superior Tool to Predict Antibody Mediated Rejection: A Single Center Experience	L.D. Glass	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Research and Immunology	0820 - The Molecular Microscope Detects Antibody-Mediated Rejection Regardless of Donor-Specific Antibody Median Fluorescence Intensity	A. Fernandez Valledor	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Research and Immunology	0821 - Multivariable Model to Predict Molecular Antibody-Mediated Rejection	A. Fernandez Valledor	27-Apr	6:00–7:00pm	Poster Hall
Poster 2 Cardiology	0880 - Donor-Derived Cell-Free DNA Assay Characteristics After Maximal Cardiopulmonary Exercise Testing in Immunologically Quiescent Heart Transplant Recipients	R.L. Gottlieb	28-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1347 - Are High Donor Derived Cell Free DNA Levels Associated with Concerning Subsequent Clinical Outcomes After Heart Transplantation?	M. Kittleson	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1380 - The Prognostic Significance of Donor-Derived Cell-Free DNA within 30 Days After Heart Transplant	M. Parades Flores	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1274 - Quilty Lesions: A Potential Marker of Allograft Dysfunction	R. Goodman	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1356 - Hidden Gems: MMDx + dd-cfDNA Identify Antibody-Mediated Rejection Not Seen on Histopathology	Y. Li	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1388 - Retrospective Study on the Diagnostic Performance of MMDx, Histopathology, and Correlation of Donor Derived Cell-Free DNA with the Nebraska Medicine Rejection Score in Heart Transplant Recipients	M. Oberoi	29-Apr	4:30–5:30pm	Poster Hall

Type	Full Title As On ISHLT Website	Abstract First Author	Session Date	Time	Location
Can I use molecular testing in this special population?					
Oral Session 11	0061 - Sex-Specific Non-Invasive Surveillance Results and Outcomes After Heart Transplant (SHORE Study)	E. DeFilippis	27-Apr	4:54–5:02pm	Ballroom C
Oral Session 11	0064 - Race Differences in Molecular Testing and Outcomes After Heart Transplant (SHORE Study)	C. Bravo	27-Apr	5:30–5:38pm	Ballroom C
Poster 3 Cardiology	1337 - Renal Dysfunction Does Not Impact Molecular Test Results Following Heart Transplantation (SHORE Study)	K. Khush	29-Apr	4:30–5:30pm	Poster Hall
Oral Session 11	0059 - Decoding Sex and Race Differences in Antibody-Mediated Rejection (ABMR): Insights from Molecular Microscope (MMDx)	A. Fernandez Valledor	27-Apr	4:30–4:38pm	Ballroom C
Oral Session 14	0086 - Noninvasive Monitoring Techniques in the Pregnant Heart Transplant Patient	S. Cipriano	27-Apr	5:33–5:38pm	Room 312
Oral Session 31	0184 - dd-cfDNA Trends After Pediatric Heart Transplant as Assessed by Per-Protocol Clinical Data	Y. Li	29-Apr	3:12–3:20pm	Ballroom B
Oral Session 31	0188 - Characteristics of Pediatric Heart Transplant Recipients with Chronically Elevated Donor Derived Cell-Free DNA in the Absence of Rejection	R.G. Lottes	29-Apr	4:00–4:08pm	Ballroom B
Mini Oral 13	0411 - Risk Assessment for DSA and Donor-Derived Cell-Free DNA in Pediatric Heart Transplant Recipients Based on HLA Molecular Mismatch	Q. Xu	29-Apr	5:12–5:16pm	Room 311
Poster 1 Cardio	0530 - Assessing Cell-Free DNA during Pregnancy in a Post Heart Transplant Recipient	C. Falke	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pediatrics	0748 - Donor Derived Cell-Free DNA is Elevated during Rejection in Pediatric Heart Transplant Recipients	B. Feingold	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pediatrics	0716 - MMDX Diagnosis of Rejection in Pediatric Heart Transplant Recipients	M.J. Bock	27-Apr	6:00–7:00pm	Poster Hall
Poster 3 Cardiology	1264 - Racial Differences in Donor-Derived Cell-Free Levels Among African American and White Heart Transplant Recipients	D. Oren	29-Apr	4:30–5:30pm	Poster Hall
What is the best way to interpret molecular testing?					
Poster 3 Cardiology	1345 - Absolute Value of GEP and dd-cfDNA Identifies Risk of ACR in Patients with Discordant Results (SHORE Study)	A. Van Bakel	29-Apr	4:30–5:30pm	Poster Hall
Oral Session 47	0284 - Frequency of Elevated Donor-Derived Cell-Free DNA Levels Not Associated with Rejection-Based on Time from Transplant	C.M. Moeller	30-Apr	1:45–1:53pm	Room 312
Poster 1 Cardiology	0570 - Impact of Primary Graft Dysfunction on Early Donor-Derived Cell Free DNA Levels	M. Sejpal	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pharmacy	0771 - Evaluating the Influence of Active Cytomegalovirus Infection on Heartcare Testing in Heart Transplant Recipients	A.L. Hua	27-Apr	6:00–7:00pm	Poster Hall
Poster 2 Cardiology	0885 - Impact of CMV Viremia on Tissue-Based Gene-Expression Profiling: Insights from the Molecular Microscope Diagnostic System (MMDx)	C.M. Moeller	28-Apr	4:30–5:30pm	Poster Hall
Poster 2 Cardiology	1346 - Advancing the Molecular Diagnosis and Characterization of Parenchymal Injury in Heart Allografts	A. Fernandez Valledor	28-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1293 - Incremental Discriminatory Performance of Donor-Derived Cell-Free DNA (dd-cfDNA) in the Assessment of Rejection in Heart Transplant (HT) Recipients	D. Oren	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1350 - Logic of High Donor Derived Cell-Free DNA and Low GEP Score After Heart Transplant Should Equal AMR, but Not So	M. Kittleson	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1381 - Donor-Derived Cell-Free DNA is Independently Associated with Cardiac Allograft Rejection and Improves Individual Risk Stratification on Top of Usual Predictive Variables (ALLOSEQ)	G. Coutance	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1277 - Senescence is Associated with Lower Peripheral Gene-Expression Profiling Levels (GEP) After Heart Transplantation (HT)	C.M. Moeller	29-Apr	4:30–5:30pm	Poster Hall

Type	Full Title As On ISHLT Website	Abstract First Author	Session Date	Time	Location
How can I use molecular testing to assess immunosuppression and response to rejection therapy?					
Oral Session 7	0036 - Impact of Daratumumab on Antibody Mediated Rejection in Heart Transplant Recipients	R. Sriwattanakomen	27-Apr	3:12–3:20pm	Room 312
Poster 1 Cardiology	0539 - Novel Use of Bortezomib and Daratumumab for Desensitization in a Highly Sensitized Heart Transplant Candidate	R. Cartus	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pharmacy	0775 - Impact of Belatacept Therapy on Gene Expression Profiling and Donor-Derived Cell-Free DNA in Heart Transplant Recipients	R. Lavelle	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pediatrics	0745 - A Single Center's Experience Using Daratumumab for Recurrent/Refractory Antibody-Mediated Rejection in Pediatric Heart Transplant Patients	A. Simonelli	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Cardiology	0538 - Donor-Derived Cell-Free DNA as a Biomarker for the Effect of Daratumumab in Patients with Antibody-Mediated Rejection Post-Heart Transplant	A. Konduri	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Pharmacy	0783 - Daratumumab for Treatment of Refractory Donor Specific Antibodies in Adult Heart Transplant Recipients	E.P. Bilgili	27-Apr	6:00–7:00pm	Poster Hall
Poster 1 Research and Immunology	0813 - Tocilizumab for Treatment of Chronic Antibody-Mediated Rejection in Heart Transplant Recipients	K. Nguyen	27-Apr	6:00–7:00pm	Poster Hall
Poster 2 Cardiology	0843 - Multiple Recurrent Mixed Rejection in a Pediatric Heart Transplant Recipient	O. Ng	28-Apr	4:30–5:30pm	Poster Hall
Poster 3 Cardiology	1375 - Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single-Center Experience	G. Rubinstein	29-Apr	4:30–5:30pm	Poster Hall
LUNG					
Oral Session 24	0143 - Multicenter Open-Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics (PK) of Tacrolimus Inhalational Powder as a Replacement to Oral Tacrolimus (TAC) in Lung Transplant (LTx) Recipients with Renal Insufficiency	G.I. Snell	29-Apr	10:24–10:32am	Ballroom B
Mini Oral 12	0403 - Impact of Tacrolimus Levels on DSA-Positive Lung Transplant Recipients	G. Rozenbaum	29-Apr	5:24–5:28pm	Room 302-304-306
Poster 2 Pulmonology	1168 - Real-World Experience of Donor-Derived Cell-Free DNA (dd-cfDNA) in Lung Transplant Recipients in a Single-Center Cohort	S. Askar	28-Apr	4:30–5:30pm	Poster Hall
Poster 3 Pulmonology	1559 - dd-cfDNA Trends in Stable Patients during First Year Following Lung Transplantation: A Large Registry Analysis (ALAMO Study)	D. Levine	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Pulmonology	1565 - Comparison of Donor Derived Cell Free DNA Fractions Between Lung and Heart-Lung Transplant Recipients	S. Pasupneti	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Pulmonology	1611 - Correlation of dd-cfDNA with Acute Rejection and Pathogenic Infection in Pediatric Lung Transplant Recipients	S. Schaffer	29-Apr	4:30–5:30pm	Poster Hall
Poster 3 Pulmonology	1627 - Utilization of Donor-Derived Cell-Free DNA (ddcfDNA) in Lung Transplant Recipients	J. Kim	29-Apr	4:30–5:30pm	Poster Hall
REMOTE MONITORING					
Poster 2 Pulmonology	1204 - Enhancing Post-Lung Transplant Care with AlloHome: Early Impact Evaluation	S. Olson	28-Apr	4:30–5:30pm	Poster Hall

To learn more about CareDx at ISHLT 2025, please visit caredx.com/ishlt2025

Session dates and time are subject to change.

This list is not intended to be an exhaustive list of any and all abstracts at ISHLT 2025 to which CareDx has contributed.

2025 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved
VTS-PRO-10688-v1 Effective 2025-04

